EnGene Therapeutics: The Selloff Creates An Opportunity

Impact · against what's priced in

The market is weighing a significant efficacy failure of enGene's sole clinical asset against a strong liquid asset position. While the cash floor provides a valuation boundary, the low 25% response rate creates a high probability of regulatory or commercial failure.

ENGN−0.20

No priced-in read yet

In context

The low 25% complete response rate for detalimogene voraplasmid suggests poor commercial viability and increased FDA risk, though this is partially offset by a cash floor of $4.66 per share.

Read from the article alone

• healthcare
• valuation
• pharmaceuticals
• biotech
• ENGN
• cash position
• clinical trials
• fda

Search tags